BioCryst Pharmaceuticals · Us_north Carolina_remote, US; Us_massachusetts_boston Office, US
· Posted 2026-10-02
· 12+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
ExecDirectorBiostatisticsclinicalregulatorywellresponsibleability
BioCryst Pharmaceuticals · Us_north Carolina_remote, US; Us_massachusetts_boston Office, US
· Posted 2026-10-01
· 15+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
DrugSubstancedevelopmentprocessmanufacturingtechnologyvalidationregulatory
BioCryst Pharmaceuticals · Multiple Locations, US
· Posted 2026-10-01
· 5+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
BilingualPatientSupportPhiladelphiaJersey
BioCryst Pharmaceuticals · Us_north Carolina_remote, US; Us_massachusetts_boston Office, US; USA Remote, US
· Posted 2026-10-01
· 8-10 years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
AssocDirectorPartnerPharmaceuticalDevelopmentdataclinicalinformation
BioCryst Pharmaceuticals · Us_north Carolina_remote, US; Us_massachusetts_boston Office, US; Us_north Carolina_headquarters, US
· Posted 2026-09-29
· 5+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
CorporateCommunicationsContentmediasocialinternalengagementemployee
BioCryst Pharmaceuticals · APAC_Japan, Country not listed
· Posted 2026-09-28
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
RareDiseaseSpecialistJapan
BioCryst Pharmaceuticals · US_North Carolina_Remote, Country not listed
· Posted 2026-09-28
· 10+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
AssocDirectorRegulatoryAffairsStrategy
BioCryst Pharmaceuticals · US_North Carolina_Remote, Country not listed
· Posted 2026-09-25
· 15+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
ExecDirectorStatisticalProgramming
BioCryst Pharmaceuticals · Us_north Carolina_remote, US; Us_massachusetts_boston Office, US
· Posted 2026-09-25
· 18+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
GCP
BioCryst Pharmaceuticals · US_North Carolina_Remote, Country not listed
· Posted 2026-09-21
· 10-12 years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
AssocDirectorAnalyticalDevelopment
BioCryst Pharmaceuticals · US_North Carolina_Remote, Country not listed
· Posted 2026-09-17
· 10+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
GCP
BioCryst Pharmaceuticals · Los Angeles, CA, US
· Posted 2026-09-17
· 5+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
SalesRareDiseaseSpecialistLosAngeles
BioCryst Pharmaceuticals · US_North Carolina_Remote, Country not listed
· Posted 2026-08-28
· 10+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
GlobalClinicalDevelopment
BioCryst Pharmaceuticals · Multiple Locations, US
· Posted 2026-08-25
· 5+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
SalesRareDiseaseSpecialistHudsonValley
BioCryst Pharmaceuticals · Multiple Locations, US
· Posted 2026-08-25
· 10+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
ExecDirectorMarketAccess
BioCryst Pharmaceuticals · Multiple Locations, Italy
· Posted 2026-08-24
· 2+ years
JOB SUMMARY: The IT Support Specialist – Frontier Durham provides dependable, customer-focused Tier 1 technical support for BioCryst employees at the Frontier Durham office. This 100% on-site role serves as the primary local IT presence for daily walk-up support, deskside assistance, hardware and software troubleshooti
SupportSpecialistOnsiteOperations
BioCryst Pharmaceuticals · North Carolina Remote, Country not listed
· Posted 2026-08-19
· 5+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
SalesRareDiseaseSpecialistDetroit
BioCryst Pharmaceuticals · North Carolina Remote, Country not listed
· Posted 2026-07-29
· 7+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
SrSystemsEngineerOnsiteSupport
BioCryst Pharmaceuticals · US_North Carolina_Remote, Country not listed
· Posted 2026-07-23
· 3+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
MSLSrPiedmontregion
BioCryst Pharmaceuticals · US_North Carolina_Remote, Country not listed
· Posted 2026-07-15
· 10+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
DirectorDrugProductDevelopment